Cargando…

Real-World Treatment Patterns of Lung Cancer in a Resource-Restricted Country: the Experience of Georgia

Lung cancer (LC) is the most common malignancy responsible for 1.8 million of deaths worldwide. Lung and bronchus cancer represents 13% (n = 1217) of all new cancer cases in Georgia. In 2018, in Georgian males lung cancer age-standardized incidence rate was 35.7/per 100 000, less compared to regiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiladze, Ivane, Mariamidze, Elene, Jeremic, Branislav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573520/
https://www.ncbi.nlm.nih.gov/pubmed/34776730
http://dx.doi.org/10.1177/11786329211055296
_version_ 1784595442660540416
author Kiladze, Ivane
Mariamidze, Elene
Jeremic, Branislav
author_facet Kiladze, Ivane
Mariamidze, Elene
Jeremic, Branislav
author_sort Kiladze, Ivane
collection PubMed
description Lung cancer (LC) is the most common malignancy responsible for 1.8 million of deaths worldwide. Lung and bronchus cancer represents 13% (n = 1217) of all new cancer cases in Georgia. In 2018, in Georgian males lung cancer age-standardized incidence rate was 35.7/per 100 000, less compared to regional countries as Turkey (70.6), Russia (48.2), Ukraine (41.7), and Armenia (58.5), but higher than in neighbor Azerbaijan (25.5). Incidence is higher compared to central and eastern Europe (27.3) and near similar to North America (34.5). Georgia is an Eastern European, middleincome country with 3.7 million residents and one of the highest numbers of active smokers in the European Region. The Georgian health care system is divided into a public and a private sector, with coverage of nearly 100% of the population. There is a national healthcare system as well as private insurance and all patients, irrespective of insurance (private or governmental) can choose the hospital for treatment by themselves all over the country. The Basic Package of the Universal Health Care Program includes the treatment of oncologic patients, specifically surgery, chemotherapy, hormone therapy and radiotherapy and investigations and medications related to these procedures. The program covers all types of laboratory and instrumental investigations related to planned treatment. Georgia lacks an LC screening program for smokers and partially because of this, the majority of patients with lung cancer present at an advanced stage. The National Centre for the Disease Control (NCDC) showed that almost 90% of LC patients in the country present with advanced stages (III-IV) with 60% of patients having stage IV disease at diagnosis . Lung cancer is generally diagnosed at an advanced stage. For non-small cell lung cancer (NSCLC), the proportion with metastatic disease (TNM stage IV) ranged from 46.8% to 61.2% in developed countries. In recent years, there have been several publications addressing specifics of LC worldwide, but none concerning Georgia. In light of the rapidly changing landscape in the diagnosis, staging, and treatment of LC, we thought to define the state of practice in Georgia by convening specialists who treat LC across 13 institutions in our country with the goal to describe differences in access and approaches to LC.
format Online
Article
Text
id pubmed-8573520
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-85735202021-11-09 Real-World Treatment Patterns of Lung Cancer in a Resource-Restricted Country: the Experience of Georgia Kiladze, Ivane Mariamidze, Elene Jeremic, Branislav Health Serv Insights Original Research Lung cancer (LC) is the most common malignancy responsible for 1.8 million of deaths worldwide. Lung and bronchus cancer represents 13% (n = 1217) of all new cancer cases in Georgia. In 2018, in Georgian males lung cancer age-standardized incidence rate was 35.7/per 100 000, less compared to regional countries as Turkey (70.6), Russia (48.2), Ukraine (41.7), and Armenia (58.5), but higher than in neighbor Azerbaijan (25.5). Incidence is higher compared to central and eastern Europe (27.3) and near similar to North America (34.5). Georgia is an Eastern European, middleincome country with 3.7 million residents and one of the highest numbers of active smokers in the European Region. The Georgian health care system is divided into a public and a private sector, with coverage of nearly 100% of the population. There is a national healthcare system as well as private insurance and all patients, irrespective of insurance (private or governmental) can choose the hospital for treatment by themselves all over the country. The Basic Package of the Universal Health Care Program includes the treatment of oncologic patients, specifically surgery, chemotherapy, hormone therapy and radiotherapy and investigations and medications related to these procedures. The program covers all types of laboratory and instrumental investigations related to planned treatment. Georgia lacks an LC screening program for smokers and partially because of this, the majority of patients with lung cancer present at an advanced stage. The National Centre for the Disease Control (NCDC) showed that almost 90% of LC patients in the country present with advanced stages (III-IV) with 60% of patients having stage IV disease at diagnosis . Lung cancer is generally diagnosed at an advanced stage. For non-small cell lung cancer (NSCLC), the proportion with metastatic disease (TNM stage IV) ranged from 46.8% to 61.2% in developed countries. In recent years, there have been several publications addressing specifics of LC worldwide, but none concerning Georgia. In light of the rapidly changing landscape in the diagnosis, staging, and treatment of LC, we thought to define the state of practice in Georgia by convening specialists who treat LC across 13 institutions in our country with the goal to describe differences in access and approaches to LC. SAGE Publications 2021-11-03 /pmc/articles/PMC8573520/ /pubmed/34776730 http://dx.doi.org/10.1177/11786329211055296 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Kiladze, Ivane
Mariamidze, Elene
Jeremic, Branislav
Real-World Treatment Patterns of Lung Cancer in a Resource-Restricted Country: the Experience of Georgia
title Real-World Treatment Patterns of Lung Cancer in a Resource-Restricted Country: the Experience of Georgia
title_full Real-World Treatment Patterns of Lung Cancer in a Resource-Restricted Country: the Experience of Georgia
title_fullStr Real-World Treatment Patterns of Lung Cancer in a Resource-Restricted Country: the Experience of Georgia
title_full_unstemmed Real-World Treatment Patterns of Lung Cancer in a Resource-Restricted Country: the Experience of Georgia
title_short Real-World Treatment Patterns of Lung Cancer in a Resource-Restricted Country: the Experience of Georgia
title_sort real-world treatment patterns of lung cancer in a resource-restricted country: the experience of georgia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573520/
https://www.ncbi.nlm.nih.gov/pubmed/34776730
http://dx.doi.org/10.1177/11786329211055296
work_keys_str_mv AT kiladzeivane realworldtreatmentpatternsoflungcancerinaresourcerestrictedcountrytheexperienceofgeorgia
AT mariamidzeelene realworldtreatmentpatternsoflungcancerinaresourcerestrictedcountrytheexperienceofgeorgia
AT jeremicbranislav realworldtreatmentpatternsoflungcancerinaresourcerestrictedcountrytheexperienceofgeorgia